Top

Published in:

01-06-2018 | Original Article

Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer

Authors: Sarah A. Ackroyd, Sajeena Thomas, Cynthia Angel, Richard Moore, Philip J. Meacham, Brent DuBeshter

Published in: Journal of Robotic Surgery | Issue 2/2018

Abstract

The objective of this study is to review our experience with robotic interval cytoreduction following neoadjuvant chemotherapy for advanced ovarian cancer. We retrospectively reviewed patients with advanced ovarian cancer treated with neoadjuvant chemotherapy (NAC) and interval robotic cytoreduction (IRC) between 2011 and 2016 at the University of Rochester Medical Center. Demographic information, chemotherapy treatment, operative results, and follow-up were extracted from medical records. Twenty-nine patients underwent IRC after a mean of 3.9 cycles of NAC. The mean operative time was 165 min with a mean EBL of 107 cc. The mean length of stay was 2.0 days. One case (3.3%) was converted to an open procedure because of extensive tumor not amenable to robotic cytoreduction. Overall, 19 (66%) patients underwent an R0 cytoreduction, 8 (28%) an optimal (<1 cm) cytoreduction, and 2 (7%) a suboptimal cytoreduction. The median overall survival was 39.7 months and median progression-free survival was 21.2 months. Interval robotic cytoreduction following NAC is feasible and may be preferable to open interval cytoreductive surgery, in specific patients, to minimize morbidity and length of hospital stay.

American Cancer Society (2015) Global cancer facts & figures, 3rd edn. American Cancer Society, Atlanta. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-factsand-figures/global-cancer-facts-and-figures-3rd-edition.pdf. Accessed 1 June 2016

American Cancer Society (2016) Survival rates for ovarian cancer, by stage. http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates. Accessed 1 Mar 2016

Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed

Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for R, Treatment of Cancer-Gynaecological Cancer G, Group NCT (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953CrossRefPubMed

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257. doi:10.1016/S0140-6736(14)62223-6 CrossRefPubMed

Ramirez PT, Adams S, Boggess JF, Burke WM, Frumovitz MM, Gardner GJ, Havrilesky LJ, Holloway R, Lowe MP, Magrina JF, Moore DH, Soliman PT, Yap S (2012) Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology’s Clinical Practice Robotics Task Force. Gynecol Oncol 124(2):180–184. doi:10.1016/j.ygyno.2011.11.006 CrossRefPubMed

Feuer GA, Lakhi N, Barker J, Salmieri S, Burrell M (2013) Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach. Gynecol Oncol 131(3):520–524. doi:10.1016/j.ygyno.2013.09.022 CrossRefPubMed

Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25(20):2873–2883. doi:10.1200/JCO.2007.11.0932 CrossRefPubMed

Magrina JF, Zanagnolo V, Noble BN, Kho RM, Magtibay P (2011) Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy. Gynecol Oncol 121(1):100–105. doi:10.1016/j.ygyno.2010.11.045 CrossRefPubMed

10.

Nezhat FR, Pejovic T, Finger TN, Khalil SS (2013) Role of minimally invasive surgery in ovarian cancer. J Minim Invasive Gynecol 20(6):754–765. doi:10.1016/j.jmig.2013.04.027 CrossRefPubMed

11.

Chen CH, Chiu LH, Chen HH, Chan C, Liu WM (2015) Comparison of robotic approach, laparoscopic approach and laparotomy in treating epithelial ovarian cancer. Int J Med Robot. doi:10.1002/rcs.1655 CrossRefPubMed

12.

Wright JD, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, Herzog TJ, Hershman DL (2013) Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA 309(7):689–698. doi:10.1001/jama.2013.186 CrossRefPubMed

13.

Melamed A, Nitecki R, Boruta DM 2nd, Del Carmen MG, Clark RM, Growdon WB, Goodman A, Schorge JO, Rauh-Hain JA (2017) Laparoscopy compared with laparotomy for debulking ovarian cancer after neoadjuvant chemotherapy. Obstet Gynecol 129(5):861–869. doi:10.1097/AOG.0000000000001851 CrossRefPubMed

14.

da Costa Miranda V, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez Diz M (2014) Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol 132(2):287–291. doi:10.1016/j.ygyno.2013.12.002 CrossRef

Title: Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer
Authors: Sarah A. Ackroyd
Sajeena Thomas
Cynthia Angel
Richard Moore
Philip J. Meacham
Brent DuBeshter
Publication date: 01-06-2018
Publisher: Springer London
Published in: Journal of Robotic Surgery / Issue 2/2018
Print ISSN: 1863-2483
Electronic ISSN: 1863-2491
DOI: https://doi.org/10.1007/s11701-017-0720-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Can dehydrated human amnion/chorion membrane accelerate the return to potency after a nerve-sparing robotic-assisted radical prostatectomy? Propensity score-matched analysis

Transoral robotic excision of a lingual thyroglossal duct cyst

A standardized analysis of the current surgical and non-surgical treatment selection process for men with localized prostate cancer

Effectiveness and feasibility of robotic gastric neurostimulator placement in patients with refractory gastroparesis

Optimization of blood loss during robotic IVC thrombectomy in a Jehovah’s witness: a case report with 14-month follow up

Tubeless outpatient robotic upper urinary tract reconstruction in the pediatric population: short-term assessment of safety